# Chemoinformatics Core

> **NIH NIH U19** · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · 2022 · $813,557

## Abstract

The Girke-chemoinformatics core will identify longevity-associated drugs and target proteins for the
genetic and molecular findings (here multi-omics hits, MOH) discovered by the other projects and cores of
the Longevity Consortium (LC). These associations will make efficient use of the large body of drug-target
interaction data available in the public domain including high-quality annotations of existing drugs, high-
throughput bioassays and gene expression data involving drug treatments. Aim 1 will systematically assess
which proteins associated with longevity MOH sets are perturbable by drugs given the data currently
available in public reference databases. Aim 2 will identify drugs inducing gene expression changes similar
to those associated with healthy aging and longevity. Aim 3 will incorporate protein family information to
compensate for the lack of bioassay information for certain proteins of interest using bioactivity information
available for closely related proteins within and across organisms. Aim 4 will prioritize drug candidates by
their level of experimental evidence, annotation and selectivity levels, as well as their potential to be useful
for drug repurposing approaches or combinatorial strategies by modulating the activity of proteins in
pathways of interest with several selective drugs or single drugs targeting multiple proteins. Aim 5 will
validate the effects of the identified drug candidates on longevity and healthy aging using the experimental
screening program of the Miller-mice/cells project. Candidate drugs passing these validation tests will be
further evaluated for downstream translational studies with LC and external advisory committee members.
Moreover, longevity drug-target networks will be computed and interrogated in close collaboration with the
Schork-disease context, Orwoll-proteomics, Fiehn-metabolomics and Perls-centenarian projects,
and the Price-systems core. Aim 6 will organize, integrate and share all analysis results and software
developed by the LC with the public by developing the LC database (LCDB) portal. Analysis methods
developed by the Girke-chemoinformatics core will be published as R packages on GitHub and
Bioconductor. Preliminary and confidential data will remain in LCDB’s private domain, while all other data
will be publicly available. In summary, the drug-target and drug-signature pairs identified by the Girke-
chemoinformatics core will have the potential of providing novel leads for translational approaches
advancing longevity research. If successful, they will enable innovative pharmacological strategies of
developing drugs or food supplements for enhancing healthy aging and longevity in humans. Detailed proof
of concept experiments have been performed, as well as an integrated pilot study together with the other
project and core teams. The large number of positive results obtained from these experiments demonstrate
the high likelihood of success of the approach.

## Key facts

- **NIH application ID:** 10448342
- **Project number:** 5U19AG023122-15
- **Recipient organization:** CALIFORNIA PACIFIC MED CTR RES INSTITUTE
- **Principal Investigator:** Thomas Girke
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $813,557
- **Award type:** 5
- **Project period:** 2004-09-30 → 2024-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10448342

## Citation

> US National Institutes of Health, RePORTER application 10448342, Chemoinformatics Core (5U19AG023122-15). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10448342. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*